PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Epitestosterone in the etiology of carcinoma of the prostate
Article published in Urologia Polska 2002/55/3.

authors

Marek Mędra¶ 1, Andrzej Basiewicz 2
1 Katedra i Klinika Endokrynologii i Diabetologii Akademii Medycznej we Wrocławiu
Kierownik kliniki: prof, dr hab. Andrzej Milewicz
2 Oddział Urologii Samodzielnego Publicznego Zespołu Opieki Zdrowotnej w Kłodzku
Ordynator oddziału: dr Bogusław Polikowski

keywords

prostate, prostate cancer, testosterone, epitestosterone

summary

The results of genetic and biochemical studies confirmed the role of androgens in prostate cancer etiopathogenesis. In these group of patients a high frequency of polymorphism of genes responsible for androgen biosynthesis, transport and metabolism was demonstrated, as well as relationship between increased androgen activity and growth factors expression in neoplasm.
Epitestosterone is an endogenous antiandrogen which can substantially modulate androgen activity in man. In the prostatic gland the level of this steroid is particularly high (from 2 to 4 times higher in comparison of the testosterone level).
Recent results showed substantially lower epitestosterone levels in prostatic cancer patients when compared with healthy men. It can be suppose that lower endogenous androgen activity may have an important role in etiopathogenesis of carcinoma of the prostate.

references

  1. 1. Shancyfelt T, Husein R, Bubley G:Hormonal predictors of prostate cancer: a meia-anaiisis. J Clin Onkol 2000; 18; 847-53.
  2. 2. Mebane C, Gibbs T, Horm J: Current status of prostate cancer in North American black males. J Nat Med. Assoc1990; 82:1118-25.
  3. 3. Ross R, Bernstein L, Lobo R, Shimizu H: 5 alfa reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-89.
  4. 4. Gann P, Hennekes C, Loncopc C:Prospective study of sex hormone levels and risk of prostate cancer. J Nat Cancer Inst 1996; 88: 1118-25.
  5. 5. Brown T: Provocative aspects of androgen genetics. Prostate (suppl.) 1996; 6: 9-12.
  6. 6. Gustafsson O, Norming U: Dihydrotestosterone and testosterone levels in men screened for prostate cancer. Br J Urol 1996; 77: 433-40.
  7. 7. Peter E: Genetic and environmental factors in prostate cancer genesis:identifying high-risk cohorts. Eur Urol 1999; 35: 362-69.
  8. 8. Ross R, Coetze GA, Pearce CL, Reichardt JK, Bretsky R Kolonel LN:Androgen metabolism and prostate cancer:establishing a model of genetic susceptibility. Eur Urol 1999; 35:355-61.
  9. 9. Story M: Polypeptide modulators of prostatic growth and development. Cancer Surg 1991; 13: 309-22.
  10. 10. Starka L, Hampl R, Hill M, Lapcik O, Bilek R, Petrik R: Epiteslosterone in human blood and prostatic tissue. Eur J Clin Biochem 1997; 35: 469-73.
  11. 11. Dehenin L, Scholler R: Depistage de la testosterone comme anabolisant ches les adolescents par la determination du rapport des excretions urinaries de testosterone el epiteslosterone.Catalog ftvoV VWQ;». 920-21
  12. 12.Hv\\\\\\\\M,Hamp\\\\^,^e\\\\ń\\\\L^,S>\\\\aiYa\\\\.-. Concentration (ˇ the endogenous anliandrogen - epiteslosterone and androgenic C-19 steroids in hipeiplaslic tissue. The Prostate 1996; 28: 347-51.
  13. 13. Weusten J, Legemaat G: The mechanism of the synthesis of16 androslenes in human testicular homogenates. J Steroid Biochem 1989; 32:689-94
  14. 14. Medra¶ M, Basicwicz A, Polkowski P, Chojniak M: Evaluation of the anliandrogen activity in men presenting bening prostatic hypoplasia and prostatic carcinoma. Int J Andr1997: 20; 80.
  15. 15. Monsalve A, Blaquier J: I\\\'arlial characterization of epididy-mal 5 alfa reductase in the rat. Steroids 1977; 30:41-51.
  16. 16. Starka L, Broulik R Hampl R, Nedvidkova J: Antirenotropic action of antiandrogenes: cyproterone acetale, casodex, fluta-mide and epiteslosterone. Endocr Rgul 1996; 30: 93-97.
  17. 17. Bicikova M, Hampl R, Hill M, Starka L: Inhibition of steroid 17 alfa hydroxylase and C 17,20 lyase in human testis by epiteslosterone. J Steroid Bioch 1993; 46: 515-18.
  18. 18. Starka L, Hampl R, Bicikova M: Observations on the biological activity of epiiestosterone. Physiol Res 1991; 40: 317-25.
  19. 19. Maucher A, von Augerer E, Hampl R:The activity of epiiestosterone in hormone dependent prostate tumor models. Endocr. Rc©i\\\\ 1994; 28:23-29.

correspondence

Andrzej Rosiewicz
ul. Sprzymierzonych 5/l
57-340 Duszniki Zdrój